Advances in Antimicrobial Resistance (AMR) — Novel Therapeutic Strategies and Diagnostics

Advances in Antimicrobial Resistance (AMR) — Novel Therapeutic Strategies and Diagnostics Abstract Antimicrobial resistance (AMR) is an escalating global health crisis characterized by the ability of microorganisms to evade treatment with once-effective drugs. The emergence and spread of resistant pathogens such as MRSA, VRE, CRE, and MDR-TB threaten the efficacy of modern medicine. The development of AMR is driven by genetic mutations, horizontal gene transfer, misuse of antibiotics, and mechanisms such as efflux pumps, biofilm formation, and enzymatic degradation of antimicrobials. This review explores innovative strategies to address AMR, focusing on advancements in diagnostics, therapeutics, and genome editing technologies. Rapid molecular diagnostics, including PCR, WGS, and microfluidics, are improving pathogen detection and resistance profiling. Therapeutically, novel antibiotics, adjuvants, vaccine strategies, combination therapy, and non-traditional approaches like quorum sensing inhibitors, phage therapy, and nanotechnology are redefining AMR management. Genomics plays a crucial role in tracking resistance genes and guiding personalized medicine. CRISPR technology, in particular, holds immense promise for disrupting resistance genes, eliminating plasmids, and developing targeted antimicrobials. Future directions emphasize integrating genomics with artificial intelligence, exploring natural product drug discovery, and leveraging synthetic biology. A multidisciplinary approach is essential to curtail AMR's impact and preserve the efficacy of antimicrobial therapies for future generations.